Peroxisome proliferator-activated receptor-α agonists modulate CXCL9 and CXCL11 chemokines in Graves' ophthalmopathy fibroblasts and preadipocytes

Molecular and Cellular Endocrinology

Volumn 349, Issue 2, 2012, Pages 255-261

  Antonelli, Alessandro ^a   Ferrari, Silvia Martina ^a   Frascerra, Silvia ^a   Ruffilli, Ilaria ^a   Gelmini, Stefania ^b   Minuto, Michele ^a   Pupilli, Cinzia ^c   Miccoli, Paolo ^a   Sellari Franceschini, Stefano ^a   Ferrannini, Ele ^a   Fallahi, Poupak ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

CXCL11; CXCL9; Cytokines; Fibroblasts; Graves' ophthalmopathy; PPAR

Indexed keywords

CIPROFIBRATE; CXCL11 CHEMOKINE; CXCL3 CHEMOKINE; FENOFIBRATE; GAMMA INTERFERON; GEMFIBROZIL; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; ANTILIPEMIC AGENT; CXCL11 PROTEIN, HUMAN; CXCL9 CHEMOKINE; CXCL9 PROTEIN, HUMAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; ENDOCRINE OPHTHALMOPATHY; ENZYME INHIBITION; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; PRIORITY JOURNAL; PROADIPOCYTE; REAL TIME POLYMERASE CHAIN REACTION; ADIPOCYTE; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE; IMMUNOLOGY; METABOLISM; PATHOLOGY; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; THYROID GLAND;

ADIPOCYTES; CHEMOKINE CXCL11; CHEMOKINE CXCL9; ENZYME-LINKED IMMUNOSORBENT ASSAY; EYE; FENOFIBRATE; FIBROBLASTS; GRAVES OPHTHALMOPATHY; HUMANS; HYPOLIPIDEMIC AGENTS; INTERFERON-GAMMA; PPAR ALPHA; PPAR DELTA; PPAR GAMMA; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; THYROID GLAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84862114003     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.11.001     Document Type: Article

References (35)

1. Antonelli A., Fallahi P., Rotondi M., Ferrari S.M., Romagnani P., Grosso M., Ferrannini E., Serio M. Increased serum CXCL10 in Graves' disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process. Eur. J. Endocrinol. 2006, 154:651-658.
2. Antonelli A., Ferrari S.M., Fallahi P., Frascerra S., Santini E., Franceschini S.S., Ferrannini E. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J. Clin. Endocrinol. Metab. 2009, 94:1803-1809.
3. Antonelli A., Ferrari S.M., Fallahi P., Piaggi S., Paolicchi A., Franceschini S.S., Salvi M., Ferrannini E. Cytokines (interferon-gamma and tumor necrosis factor-alpha)-induced nuclear factor-kappaB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone. Metabolism 2011, 60:277-283.
4. Antonelli A., Ferrari S.M., Frascerra S., Pupilli C., Mancusi C., Metelli M.R., Orlando C., Ferrannini E., Fallahi P. CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves' and normal thyrocytes. J. Clin. Endocrinol. Metab. 2010, 95:E413-E420.
5. Antonelli A., Rotondi M., Fallahi P., Grosso M., Boni G., Ferrari S.M., Romagnani P., Serio M., Mariani G., Ferrannini E. Iodine-131 given for therapeutic purposes modulates differently interferon-gamma-inducible alpha-chemokine CXCL10 serum levels in patients with active Graves' disease or toxic nodular goiter. J. Clin. Endocrinol. Metab. 2007, 92:1485-1490.
6. Antonelli A., Rotondi M., Fallahi P., Romagnani P., Ferrari S.M., Buonamano A., Ferrannini E., Serio M. High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism. J. Clin. Endocrinol. Metab. 2004, 89:5496-5499.
7. Antonelli A., Rotondi M., Ferrari S.M., Fallahi P., Romagnani P., Franceschini S.S., Serio M., Ferrannini E. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists. J. Clin. Endocrinol. Metab. 2006, 91:614-620.
8. Bahn R.S., Gorman C.A., Johnson C.M., Smith T.J. Presence of antibodies in the sera of patients with Graves' disease recognizing a 23 kilodalton fibroblast protein. J. Clin. Endocrinol. Metab. 1989, 69:622-628.
9. Chawla A., Barak Y., Nagy L., Liao D., Tontonoz P., Evans R.M. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 2001, 7:48-52.
10. Cunard R., Ricote M., DiCampli D., Archer D.C., Kahn D.A., Glass C.K., Kelly C.J. Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. J. Immunol. 2002, 168:2795-2802.
11. Delerive P., De Bosscher K., Besnard S., Vanden Berghe W., Peters J.M., Gonzalez F.J., Fruchart J.C., Tedgui A., Haegeman G., Staels B. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J. Biol. Chem. 1999, 274:32048-32054.
12. Delerive P., Gervois P., Fruchart J.C., Staels B. Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J. Biol. Chem. 2000, 275:36703-36707.
13. Desvergne B., Wali W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 1999, 20:649-688.
14. Garcià-Lòpez M.A., Sancho D., Sànchez-Madrid F., Marazuela M. Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3+ lymphocytes. J. Clin. Endocrinol. Metab. 2001, 86:5008-5016.
15. Graham D.J., Ouellet-Hellstrom R., MaCurdy T.E., Ali F., Sholley C., Worrall C., Kelman J.A. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010, 304:411-418.
16. Issemann I., Prince R.A., Tugwood J.D., Green S. The peroxisome proliferator-activated receptor: retinoid X receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs. J. Mol. Endocrinol. 1993, 11:37-47.
17. Jiang C., Ting A.T., Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391:82-86.
18. Kwon J.H., Keates S., Simeonidis S., Grall F., Libermann T.A., Keates A.C. ESE-1, an enterocyte-specific Ets transcription factor, regulates MIP-3 gene expression in Caco-2 human colonic epithelial cells. J. Biol. Chem. 2003, 278:875-884.
19. Lee J.W., Bajwa P.J., Carson M.J., Jeske D.R., Cong Y., Elson C.O., Lytle C., Straus D.S. Fenofibrate represses interleukin-17 and interferon-gamma expression and improves colitis in interleukin-10 deficient mice. Gastroenterology 2007, 133:108-123.
20. Lehmann G.M., Garcia-Bates T.M., Smith T.J., Feldon S.E., Phipps R.P. Regulation of lymphocyte function by PPARgamma: relevance to thyroid eye disease-related inflammation. PPAR Res. 2008, 2008:895901.
21. Lehmann J.M., Lenhard J.M., Oliver B.B., Ringold G.M., Kliewer S.A. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 1997, 272:3406-3410.
22. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
23. Lombardi A., Cantini G., Piscitelli E., Gelmini S., Francalanci M., Mello T., Ceni E., Varano G., Forti G., Rotondi M., Galli A., Serio M., Luconi M. A new mechanism involving ERK contributes to rosiglitazone inhibition of tumor necrosis factor-alpha and interferon-gamma inflammatory effects in human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2008, 28:718-724.
24. Lovett-Racke A.E., Hussain R.Z., Northrop S., Choy J., Rocchini A., Matthes L., Chavis J.A., Diab A., Drew P.D., Racke M.K. Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease. J. Immunol. 2004, 172:5790-5798.
25. Marx N., Mach F., Sauty A., Leung J.H., Sarafi M.N., Ransohoff R.M., Libby P., Plutzky J., Luster A.D. Peroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J. Immunol. 2000, 164:6503-6508.
26. Moynihan R. European drug agency extends review of safety of pioglitazone. Br. Med. J. 2011, 342:d4105.
27. Nie M., Corbett L., Knox A.J., Pang L. Differential regulation of chemokine expression by peroxisome proliferator-activated receptor gamma agonists: interactions with glucocorticoids and beta2-agonists. J. Biol. Chem. 2004, 280:2550-2561.
28. Pascual G., Fong A.L., Ogawa S., Gamliel A., Li A.C., Perissi V., Rose D.W., Willson T.M., Rosenfeld M.G., Glass C.K. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005, 437:759-763.
29. Pasquali D., Pierantoni G.M., Fusco A., Staibano S., Colantuoni V., De Bellis A., Bellastella A., Sinisi A.A. Fenofibrate increases the expression of high mobility group AT-hook 2 (HMGA2) gene and induces adipocyte differentiation of orbital fibroblasts from Graves' ophthalmopathy. J. Mol. Endocrinol. 2004, 33:133-143.
30. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391:79-82.
31. Romagnani S. The Th1/Th2 paradigm. Immunol. Today 1997, 18:263-266.
32. Schaefer K.L., Denevich S., Ma C., Cooley S.R., Nakajima A., Wada K., Schlezinger J., Sherr D., Saubermann L.J. Intestinal antiinflammatory effects of thiazolidenedione peroxisome proliferator-activated receptor-gamma ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms. Inflamm. Bowel Dis. 2005, 11:244-252.
33. Spencer N.F., Poynter M.E., Im S.Y., Daynes R.A. Constitutive activation of NF-kappaB in an animal model of aging. Int. Immunol. 1997, 9:1581-1588.
34. Starkey K., Heufelder A., Baker G., Joba W., Evans M., Davies S., Ludgate M. Peroxisome proliferator-activated receptor-gamma in thyroid eye disease: contraindication for thiazolidinedione use?. J. Clin. Endocrinol. Metab. 2003, 88:55-59.
35. Valyasevi R.W., Harteneck D.A., Dutton C.M., Bahn R.S. Stimulation of adipogenesis, peroxisome proliferator-activated receptor-gamma (PPARgamma), and thyrotropin receptor by PPARgamma agonist in human orbital preadipocyte fibroblasts. J. Clin. Endocrinol. Metab. 2002, 87:2352-2358.